[Skip to Navigation]
Sign In
February 24, 2010

Incomplete Financial Disclosures in an Editorial, Clinical Crossroads, and Reply Letter Related to Herpes Zoster

JAMA. 2010;303(8):733-734. doi:10.1001/jama.2010.109

To the Editor: I would like to report incomplete financial disclosures related to an Editorial,1 a Clinical Crossroads article,2 and a subsequent reply to a letter to the editor3 published in JAMA. This resulted from my misinterpretation of JAMA requirements for reporting conflicts of interest. As I noted previously,1-3 I am on the board of directors of Gilead Sciences and a consultant for Chimerix; I receive compensation and stock from both companies. Neither company is involved in the development of drugs to treat herpesvirus infections. However, I did not report 3 financial disclosure issues.

Add or change institution